Abstract
Famciclovir is an antiviral with efficacy and safety comparable to aciclovir, but famciclovir's more favorable pharmacokinetic profile enables a less frequent dosing regimen. Future trials will likely determine famciclovir's role in the suppression of HBV.
Full Text
The Full Text of this article is available as a PDF (379.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Boike S. C., Pue M. A., Freed M. I., Audet P. R., Fairless A., Ilson B. E., Zariffa N., Jorkasky D. K. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Clin Pharmacol Ther. 1994 Apr;55(4):418–426. doi: 10.1038/clpt.1994.51. [DOI] [PubMed] [Google Scholar]
- Böker K. H., Ringe B., Krüger M., Pichlmayr R., Manns M. P. Prostaglandin E plus famciclovir--a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation. 1994 Jun 27;57(12):1706–1708. [PubMed] [Google Scholar]
- Cirelli R., Herne K., McCrary M., Lee P., Tyring S. K. Famciclovir: review of clinical efficacy and safety. Antiviral Res. 1996 Mar;29(2-3):141–151. doi: 10.1016/0166-3542(95)00941-8. [DOI] [PubMed] [Google Scholar]
- Filer C. W., Allen G. D., Brown T. A., Fowles S. E., Hollis F. J., Mort E. E., Prince W. T., Ramji J. V. Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects. Xenobiotica. 1994 Apr;24(4):357–368. doi: 10.3109/00498259409045899. [DOI] [PubMed] [Google Scholar]
- Perry C. M., Wagstaff A. J. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs. 1995 Aug;50(2):396–415. doi: 10.2165/00003495-199550020-00011. [DOI] [PubMed] [Google Scholar]
- Sacks S. L., Aoki F. Y., Diaz-Mitoma F., Sellors J., Shafran S. D. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA. 1996 Jul 3;276(1):44–49. [PubMed] [Google Scholar]
- Saltzman R., Jurewicz R., Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother. 1994 Oct;38(10):2454–2457. doi: 10.1128/aac.38.10.2454. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shaw T., Amor P., Civitico G., Boyd M., Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother. 1994 Apr;38(4):719–723. doi: 10.1128/aac.38.4.719. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tsiquaye K. N., Slomka M. J., Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J Med Virol. 1994 Mar;42(3):306–310. doi: 10.1002/jmv.1890420319. [DOI] [PubMed] [Google Scholar]
- Tyring S., Barbarash R. A., Nahlik J. E., Cunningham A., Marley J., Heng M., Jones T., Rea T., Boon R., Saltzman R. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995 Jul 15;123(2):89–96. doi: 10.7326/0003-4819-123-2-199507150-00002. [DOI] [PubMed] [Google Scholar]
- Vere Hodge R. A., Sutton D., Boyd M. R., Harnden M. R., Jarvest R. L. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother. 1989 Oct;33(10):1765–1773. doi: 10.1128/aac.33.10.1765. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weller S., Blum M. R., Doucette M., Burnette T., Cederberg D. M., de Miranda P., Smiley M. L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993 Dec;54(6):595–605. doi: 10.1038/clpt.1993.196. [DOI] [PubMed] [Google Scholar]